Vascular Solutions Inc (VASC.W)
8.61USD
9 Feb 2010
$0.16 (+1.86%)
$8.61
--
$8.70
$8.52
103,635
48,347
$9.80
$5.04
VASC.W
About
Overall
| Beta: | 0.50 |
| Market Cap (Mil.): | $146.58 |
| Shares Outstanding (Mil.): | 16.73 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| VASC.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.75 | 4.05 | 3.76 |
| EPS (TTM): | -67.12 | -- | -- |
| ROI: | 13.08 | 2.37 | 2.30 |
| ROE: | 14.89 | 3.77 | 2.82 |
HEADLINE STOCKS-Some U.S. stocks to watch on Oct. 13
NEW YORK, Oct 13 (Reuters) - Some U.S. stocks to watch on Tuesday:
UPDATE 1-Vascular Solutions gets FDA OK on blood clotting device
* Gets FDA clearance for Guardian II hemostasis valve * Shares rise 31 pct in after-hours trade
Vascular jumps after FDA clearance
NEW YORK (Reuters) - Vascular Solutions Inc shares jumped 15 percent to $9.60 in extended trade on Monday after the company, along with Zerusa Limited, were granted U.S. Food and Drug Administration market clearance for the Guardian II hemostasis valve.
AFTER THE BELL-Vascular jumps after FDA clearance
NEW YORK, Oct 12 (Reuters) - Vascular Solutions Inc shares jumped 15 percent to $9.60 in extended trade on Monday after the company, along with Zerusa Limited, were granted U.S. Food and Drug Administration market clearance for the Guardian II hemostasis valve. [ID:nWNAB8199]
HEADLINE STOCKS-U.S. stocks on the move on April 17
(Updates to afternoon trading, adds McDonald's, Superior and Zumiez)
US RESEARCH SUMMARY-Non-S&P 500 April 17 1407 GMT
Following is a summary of research actions on non-S&P 500 companies reported
HEADLINE STOCKS-U.S. stocks on the move on April 17
NEW YORK, April 17 (Reuters) - Some U.S. stocks on the move on Friday:
HEADLINE STOCKS-U.S. stocks to watch on April 17
NEW YORK, April 17 (Reuters) - Some U.S. stocks to watch on Friday:
CORRECTED - CORRECTED-UPDATE 1-Vascular Solutions posts in line Q1 EPS; sees
(Corrects headline, bullet points and paragraph 1 to show that company's first-quarter earnings per share was in line with market expectations, and not below consensus. Also changes estimate comparisons for second-quarter and full-year outlook.)
US RESEARCH SUMMARY-Non-S&P 500 April 9 1657 GMT
Following is a summary of research actions on non-S&P 500 companies reported
Competitors
| Price | Change | |
|---|---|---|
| Medtronic, Inc. (MDT.N) | $42.36 | +0.57 |
| Abbott Laboratories (ABT.N) | $53.35 | 0.00 |
| Johnson & Johnson (JNJ.N) | $62.76 | +0.39 |
| Boston Scientific Corporation (BSX.N) | $8.23 | +0.08 |
| AngioDynamics, Inc. (ANGO.OQ) | $16.01 | 0.00 |
| Biolitec AG (BIBG.DE) | €-- | -- |
| VNUS Medical Technologies, Inc. (VNUS.OQ) | -- | -- |
| St. Jude Medical, Inc. (STJ.N) | $37.70 | +0.30 |
| Kensey Nash Corporation (KNSY.OQ) | $20.44 | +0.56 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
